Aura Biosciences, INC. (AURA) — 10-Q Filings

All 10-Q filings from Aura Biosciences, INC.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (5)

Aura Biosciences' Losses Widen on Soaring R&D for Lead Candidate — Nov 13, 2025 Risk: high
Aura Biosciences, Inc. reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $80.632 million, up from $61.085 milli
Aura Biosciences' Net Loss Widens Amid R&D Surge, Bolstered by $70M Offering — Aug 13, 2025 Risk: high
Aura Biosciences, Inc. (AURA) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $54.502 million, up from $40.043 mill
Aura Biosciences Q1 2025 Update — May 15, 2025 Risk: medium
Aura Biosciences, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including its cash and cash equival
Aura Biosciences Q3 2024 Update — Nov 12, 2024 Risk: medium
Aura Biosciences, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance and business operations, inclu
Aura Biosciences Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
Aura Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on biological products, reported financial information for the s

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX